FDA Submission Update for Dalfampridine by Accord Healthcare
Accord Healthcare has submitted an Abbreviated New Drug Application (ANDA) for Dalfampridine, currently under standard review.
Asset / Drug
Drug and asset intelligence for Dalfampridine with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.